1. Home
  2. KEEL vs CAPR Comparison

KEEL vs CAPR Comparison

Compare KEEL & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Keel Infrastructure Corp. Common Stock

KEEL

Keel Infrastructure Corp. Common Stock

N/A

Current Price

$4.00

Market Cap

1.9B

Sector

Finance

ML Signal

N/A

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

HOLD

Current Price

$3.91

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KEEL
CAPR
Founded
N/A
2005
Country
Canada
United States
Employees
274
N/A
Industry
Finance: Consumer Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.6B
IPO Year
N/A
2011

Fundamental Metrics

Financial Performance
Metric
KEEL
CAPR
Price
$4.00
$3.91
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$44.63
AVG Volume (30 Days)
29.0M
4.9M
Earning Date
N/A
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$3.31
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.17
$2.96
52 Week High
$7.37
$40.37

Technical Indicators

Market Signals
Indicator
KEEL
CAPR
Relative Strength Index (RSI) 37.79 11.43
Support Level $3.41 N/A
Resistance Level $5.03 $6.81
Average True Range (ATR) 0.43 1.37
MACD 0.01 -1.63
Stochastic Oscillator 40.70 5.06

Price Performance

Historical Comparison
KEEL
CAPR

About KEEL Keel Infrastructure Corp. Common Stock

Keel Infrastructure Corp is a North American digital infrastructure and energy company that develops and owns data centers and energy infrastructure for high-performance computing workloads, including AI. The group has a pipeline of 2.2 gigawatts and established grid interconnections already in place. It delivers scalable infrastructure solutions in high-demand power markets across Pennsylvania and Washington in the United States, and Quebec in Canada. It has data campuses in Moses Lake, Panther Creek, Sharon, Sherbrooke, and Scrubgrass.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: